Thomas E. Friebel

Tom Friebel's practice focuses on patent interferences and prosecution of patent portfolios with applications or patents that are expected to become involved in interferences. Tom also handles district court actions seeking review of interference decisions of the Board of Patent Appeals and Interferences (35 U.S.C. § 146) and appeals of interferences to the Court of Appeals for the Federal Circuit (35 U.S.C. § 141). His practice also includes complex patent prosecutions, patent opinions, and patent infringement litigations as well.

Having handled more than 50 patent interferences, Tom has a seasoned understanding of interference substantive law and procedure and has demonstrated versatility in interferences in a wide variety of technologies, particularly in the fields of biotechnology and pharmaceuticals. Representative interferences include Idenix Pharmaceuticals' two interferences against Gilead Pharmasset involving nucleosides for treating HCV, PDL BioPharma's two interferences against UCB Pharma involving certain humanized antibodies, Sepracor's three interferences against Wyeth involving the drug ODMV succinate, Hoffmann-La Roche and Genentech's two interferences against Japan Foundation for Cancer Research involving recombinant human fibroblast (beta) interferon, Hoffmann-La Roche and Genentech's interference against Biogen involving recombinant human leukocyte (alpha) interferon, Hoffmann-La Roche's interference against Enzon Pharmaceuticals involving pegylated human leukocyte (alpha) interferon, Boston Scientific's interference and action under 35 U.S.C. § 146 against Medtronic involving bifurcated stent/grafts for treating abdominal aortic aneurysms, and Searle and Pfizer's interference against Merck Frosst Canada involving non-steroidal anti-inflammatory compounds that selectively inhibit the cyclooxygenase-2 (COX-2) enzyme. [1]